Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors.

Authors:
Luca Pasquini Alessia Petronelli Eleonora Petrucci Ernestina Saulle Gualtiero Mariani Giovanni Scambia Pierluigi Benedetti-Panici Stefano Greggi Francesco Cognetti Ugo Testa

Int J Oncol 2010 Mar;36(3):707-13

Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.

Resistance of tumors to cell death signals poses a complex clinical problem. In the present study, we have explored the capacity of proteasome inhibitors to induce cell death of ovarian cancer cells. We explored the sensitivity of primary ovarian cancer cells to a combination of bortezomib (also known as PS-341), a proteasome inhibitor and TRAIL, a death ligand, or mapatumumab or lexatumumab, TRAIL-R1 or TRAIL-R2 targeting agonist monoclonal antibodies, respectively. The results of our study showed that the large majority of primary ovarian cancers are clearly sensitive to the pro-apoptotic action of bortezomib, whose effects are potentiated by the concomitant addition of TRAIL or mapatumumab or lexatumumab. Interestingly, both cisplatin and paclitaxel-chemosensitive and chemoresistant ovarian tumors are equally sensitive to the cytotoxic effect of bortezomib. Bortezomib, combined with TRAIL or TRAIL-R1 or TRAIL-R2 agonist monoclonal antibodies may be a useful treatment for refractory ovarian cancer.

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo_00000546DOI Listing
March 2010

Publication Analysis

Top Keywords

ovarian cancer
16
cancer cells
12
primary ovarian
12
trail-r1 trail-r2
8
proteasome inhibitors
8
agonist monoclonal
8
monoclonal antibodies
8
cell death
8
mapatumumab lexatumumab
8
ovarian
5
pro-apoptotic action
4
action bortezomib
4
large majority
4
sensitive pro-apoptotic
4
ovarian cancers
4
cancers clearly
4
clearly sensitive
4
study large
4
majority primary
4
targeting agonist
4

Keyword Occurance

Similar Publications

Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.

Authors:
Ying Chen Fangxuan Li Dan Li Wenxin Liu Lei Zhang

Clin Immunol 2021 Apr 17:108728. Epub 2021 Apr 17.

Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China; National Clinical Research Centre of Cancer, Tianjin 300060, China. Electronic address:

Objective: To investigate the relationship between lncRNA PVT1(PVT1) level and PD-L1 expression and their functions in cisplatin resistant epithelial ovarian cancer (CREOC).

Methods: PVT1 and PD-L1 in ovarian cancer tissues were detected and analyzed. The cells proliferation, apoptosis, invasion abilities and potential mechanism were detected by cell functional experiments and western-blot assay, respectively. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Clinicopathologic Characteristics and Survival of Patients with Rare Malignant Ovarian Yolk Sac Tumors: A Population-based Analysis.

Authors:
Tian Wang Bo Wang Shi-Xuan Wang Ming-Fu Wu

Curr Med Sci 2021 Apr 20;41(2):342-347. Epub 2021 Apr 20.

Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Yolk sac tumors (YSTs) are rare malignant germ cell tumors that usually affect young females. To date, there have been few studies on YSTs. We evaluated the relationship between clinicopathologic characteristics of patients with ovarian YSTs and disease outcome based on Surveillance, Epidemiology, and End Results data. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

The potential role of miR-124-3p in tumorigenesis and other related diseases.

Authors:
Qian Li Shuqing Liu Jinsong Yan Ming-Zhong Sun Frederick T Greenaway

Mol Biol Rep 2021 Apr 20. Epub 2021 Apr 20.

Carlson School of Chemistry and Biochemistry, Clark University, Worcester, MA, 01610, USA.

MicroRNAs (miRNAs) are a class of single-stranded noncoding and endogenous RNA molecules with a length of 18-25 nucleotides. Previous work has shown that miR-124-3p leads to malignant progression of cancer including cell apoptosis, migration, invasion, drug resistance, and also recovers neural function, affects adipogenic differentiation, facilitates wound healing through control of various target genes. miR-124-3p has been mainly previously characterized as a tumor suppressor regulating tumorigenesis and progression in several cancers, such as hepatocellular carcinoma (HCC), gastric cancer (GC), bladder cancer, ovarian cancer (OC), and leukemia, as a tumor promotor in breast cancer (BC), and it has been also widely studied in a variety of neurological diseases, like Parkinson's disease (PD), dementia and Alzheimer's disease (AD), and cardiovascular diseases, ulcerative colitis (UC), acute respiratory distress syndrome (ARDS). Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Dissection of the potential pharmacological function of neohesperidin dihydrochalcone - a food additive - by substances profiling and network pharmacology.

Authors:
Feng-Xiang Zhang Yu-Lin-Lan Yuan Shuang-Shuang Cui Min Li Xuan Tan Zuo-Cheng Qiu Rui-Man Li

Food Funct 2021 Apr 20. Epub 2021 Apr 20.

Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China.

Food additives are widely used in our daily life, and the side-effects caused by them have gained extensive attention around the world. Notably, constituent-oriented metabolites, in some sense, always contribute to pharmacological changes, inducing toxicity, therapeutic effects, etc. Characterization of the metabolites and their potential functions is of great importance to the practical applications. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Universal access to genetic counseling for women with epithelial ovarian cancer in Nova Scotia: Evaluating a new collaborative care model.

Authors:
Ashley Warias Meghan Ferguson Erin Chamberlain Lauren Currie Nicole Snow Kara Matheson Lynette S Penney Katharina Kieser

J Genet Couns 2021 Apr 19. Epub 2021 Apr 19.

Division of Gynaecologic Oncology, Dalhousie University, Halifax, NS, Canada.

Women with pathogenic variants in BRCA1/2 have a significantly increased lifetime risk of breast and ovarian cancers. The availability of genetic testing to identify BRCA1/2 carriers is imperative to disease prevention and treatment. We evaluated the effectiveness of a new collaborative care model in Nova Scotia, involving the integration of genetic counselors into tumor board rounds, reduction in time allotted for initial genetic counseling appointments from 60 to 45 min, and a standardized dictation template, to increase referral rate for genetic counseling. Read More

View Article and Full-Text PDF
April 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap